Aseptic filling of parenterals is one of the most challenging tasks within pharmaceutical manufacturing. There is a wide range of challenges from engineer driven tasks like filling accuracy and machine performance to pharmaceutical key questions like how to keep the process sterile while staying compliant with the regulations and guidelines. All of this is influenced by new process methods and innovations in technology and at the same time trying to remain cost effective and make the right decisions quickly.
At the 2019 ISPE Aseptic Conference, you will learn firsthand from people within the industry who are facing these challenges and how they have dealing with them. The sessions, workshops, networking breaks, and social events give you a unique opportunity to discuss the challenges you’re currently facing and gain some actionable ideas and solutions to improve the manufacturing processes at your company.
For the first time, we will have a session for cell and gene therapy! Production systems for this application are challenging for manufacturing operations as the requirements are different from the traditional aseptic fill-finish process. Production limitations may include the culture of modified live cells and very small batch sizes (one patient/batch), as the therapies are highly specialized. In this session, we will cover case-studies from recently completed projects, including lessons learned and an outlook of what’s to come in the future.
An on-going area of interest is disposable equipment and how it is finding its way into the whole production chain and now conquering the last route, the fill/finish path. Sessions include:
I am honored to be the wingman of our chair, Jörg Zimmermann, for the aseptic track for the 6th year in a row and look forward to connecting with you at the 2019 ISPE Aseptic Conference.
In the pharmaceutical industry, which is highly regulated, aseptic processing is a critical component that ensures the sterility of products. Regulators have a set of comprehensive requirements that minimize the risk of contamination. Regulators set the requirements; however, the industry has an obligation to the patients who rely on and expect a drug that is safe and free of contamination....
Like any investment in digital manufacturing systems, demonstrating business payback before and after investment is critical to getting MES projects approved and verifying profitability after investment. Whether it is introducing MES, expanding it to additional sites, switching software, upgrading existing software, or developing electronic production records (EPR) for new drug products,...
Sustainability is emerging as a pivotal force influencing the pharmaceutical industry’s dynamics and steering companies towards transformative change. The focus of this analysis is to delve into the sustainability key performance indicators (KPIs) of prominent pharmaceutical players, namely Pfizer, Sanofi, Glaxo Smith Kline (GSK), Becton Dickinson, Johnson & Johnson, Abbott, Eli Lilly, and...